| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60b9c44857fe2d9d6716a0eabea0a78e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6951
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-0015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08L5-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4875 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 |
| filingDate |
2018-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5994382e9c20c8174b9105b4f9a4a216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d26670ec0ec1d57d62c6c7d7faf120e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_501e7dc41daf6361306ecd3e053557bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ed2331ae0bf5ce538e7d4e1deb3d609 |
| publicationDate |
2020-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110662550-A |
| titleOfInvention |
Oral administration of physiologically active substances |
| abstract |
Embodiments of the present invention may include a composition for oral drug delivery. The composition may contain a physiologically active substance, a carrier compound, a mucoadhesive compound, and a penetration enhancer. Physiologically active substances can be transported across the stomach. Physiologically active substances are stable and do not degrade in the harsh gastric acid environment. In order to help protect the physiologically active substance, the physiologically active substance may be mixed with a carrier. The carrier can be a liquid that does not dissolve in the stomach acid of the stomach. The physiologically active substance can be dissolved in the carrier. Mucoadhesive compounds can be used to facilitate absorption of physiologically active substances into the lining of the stomach. Penetration enhancers facilitate the transport of physiologically active substances through the stomach wall. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113053453-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022184166-A1 |
| priorityDate |
2017-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |